Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open

Remo Panaccione; Maria T. Abreu; Irina Lazariciu; Rajiv Mundayat; Nervin Lawendy; Leonardo Salese; John C. Woolcott; Bruce E. Sands; María Chaparro

doi:10.1111/apt.16848

Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open

Remo Panaccione, Maria T. Abreu, Irina Lazariciu, Rajiv Mundayat, Nervin Lawendy, Leonardo Salese, John C. Woolcott, Bruce E. Sands, María Chaparro

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Original language	English
Pages (from-to)	1534-1544
Number of pages	11
Journal	Alimentary Pharmacology and Therapeutics
Volume	55
Issue number	12
DOIs	https://doi.org/10.1111/apt.16848
State	Published - Jun 2022

Access to Document

10.1111/apt.16848

Cite this

Panaccione, R., Abreu, M. T., Lazariciu, I., Mundayat, R., Lawendy, N., Salese, L., Woolcott, J. C., Sands, B. E., & Chaparro, M. (2022). Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open. Alimentary Pharmacology and Therapeutics, 55(12), 1534-1544. https://doi.org/10.1111/apt.16848

@article{565744ea4eb440d8bde5ab4659831e0f,

title = "Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open",

author = "Remo Panaccione and Abreu, {Maria T.} and Irina Lazariciu and Rajiv Mundayat and Nervin Lawendy and Leonardo Salese and Woolcott, {John C.} and Sands, {Bruce E.} and Mar{\'i}a Chaparro",

note = "Funding Information: This study was sponsored by Pfizer. Medical writing support, under the guidance of the authors, was provided by Helen Findlow, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (. 2015;163:461–464). Irina Lazariciu is an employee of IQVIA, which was a paid contractor to Pfizer in connection with the development of this manuscript and in providing statistical support. Funding information Ann Intern Med Funding Information: The authors thank the patients, physicians and trial team involved in OCTAVE Open. Medical writing support, under the guidance of the authors, was provided by Helen Findlow, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (. 2015;163:461–464). Irina Lazariciu is an employee of IQVIA, which was a paid contractor to Pfizer in connection with the development of this manuscript and in providing statistical support. Ann Intern Med Funding Information: RP has received advisory and/or consultation fees from AI4GI, AbbVie, Amgen, Arena Pharmaceuticals, Atlantic Healthcare, BioBalance, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Coronado Biosciences, Cosmo Technologies, Eagle, Eisai Medical Research, Elan, Eli Lilly, EnGene, Ferring Pharmaceuticals, Genentech, Gilead Sciences, Given Imaging, GlaxoSmithKline, Innomar, Janssen, Lycera, Meda, Merck & Co., Merck Research Laboratories, Novo Nordisk, PDL Biopharma, Pfizer Inc, Prometheus Laboratories, Protagonist, Receptos, Robarts Clinical Trials, Sandoz, Sanofi Genzyme, Satisfai Health, Shire Pharmaceuticals, Sigmoid Pharma, Specialty Rx, Sublimity, Takeda and TherAdvance. MTA has served as a trainer/lecturer for Cornerstones Health, Inc, Focus Medical Communications, Imedex, Janssen and Prime CME; and has served as a consultant or advisor to AbbVie, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Bristol‐Myers Squibb, Eli Lilly, Gilead Sciences, Prometheus Biosciences, Takeda and UCB Biopharma SRL. IL is an employee of IQVIA, which was a paid contractor to Pfizer in connection with the development of this manuscript and in providing statistical support. RM, NL, LS and JCW are all employees and stockholders of Pfizer Inc. BES has received consulting fees from 4D Pharma, AbbVie, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Boston Pharmaceuticals, Capella Biosciences, Celgene, Celltrion Healthcare, Eli Lilly, EnGene, Ferring Pharmaceuticals, Genentech, Gilead Sciences, Hoffmann‐La Roche, Immunic, Ironwood Pharmaceuticals, Janssen, Lyndra, MedImmune, Morphic Therapeutic, Oppilan Pharma, OSE Immunotherapeutics, Otsuka, Palatin Technologies, Pfizer Inc, Progenity, Prometheus Laboratories, Redhill Biopharma, Rheos Medicines, Seres Therapeutics, Shire Pharmaceuticals, Synergy Pharmaceuticals, Takeda, Target RWE, Theravance Biopharma R&D, TiGenix and Vivelix Pharmaceuticals; has received honoraria for speaking in CME programmes from Eli Lilly, Genetech, Gilead Sciences, Janssen, Pfizer Inc and Takeda; and has received research funding from Celgene, Janssen, Pfizer Inc, Takeda and Theravance Biopharma R&D. MC has served as a speaker, consultant and advisory member for, or received research funding from, AbbVie, Celltrion, Chiesi, Faes Farma, Falk Pharma, Ferring Pharmaceuticals, Gebro Pharma, Janssen, MSD, Otsuka Pharmaceuticals, Pfizer Inc, Roche, Shire Pharmaceuticals, Takeda and Tillotts Pharma. ",

year = "2022",

month = jun,

doi = "10.1111/apt.16848",

language = "English",

volume = "55",

pages = "1534--1544",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "12",

}

Panaccione, R, Abreu, MT, Lazariciu, I, Mundayat, R, Lawendy, N, Salese, L, Woolcott, JC, Sands, BE & Chaparro, M 2022, 'Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open', Alimentary Pharmacology and Therapeutics, vol. 55, no. 12, pp. 1534-1544. https://doi.org/10.1111/apt.16848

Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open. / Panaccione, Remo; Abreu, Maria T.; Lazariciu, Irina et al.
In: Alimentary Pharmacology and Therapeutics, Vol. 55, No. 12, 06.2022, p. 1534-1544.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy

T2 - data from the open-label, long-term extension study, OCTAVE open

AU - Panaccione, Remo

AU - Abreu, Maria T.

AU - Lazariciu, Irina

AU - Mundayat, Rajiv

AU - Lawendy, Nervin

AU - Salese, Leonardo

AU - Woolcott, John C.

AU - Sands, Bruce E.

AU - Chaparro, María

N1 - Funding Information: This study was sponsored by Pfizer. Medical writing support, under the guidance of the authors, was provided by Helen Findlow, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (. 2015;163:461–464). Irina Lazariciu is an employee of IQVIA, which was a paid contractor to Pfizer in connection with the development of this manuscript and in providing statistical support. Funding information Ann Intern Med Funding Information: The authors thank the patients, physicians and trial team involved in OCTAVE Open. Medical writing support, under the guidance of the authors, was provided by Helen Findlow, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (. 2015;163:461–464). Irina Lazariciu is an employee of IQVIA, which was a paid contractor to Pfizer in connection with the development of this manuscript and in providing statistical support. Ann Intern Med Funding Information: RP has received advisory and/or consultation fees from AI4GI, AbbVie, Amgen, Arena Pharmaceuticals, Atlantic Healthcare, BioBalance, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Coronado Biosciences, Cosmo Technologies, Eagle, Eisai Medical Research, Elan, Eli Lilly, EnGene, Ferring Pharmaceuticals, Genentech, Gilead Sciences, Given Imaging, GlaxoSmithKline, Innomar, Janssen, Lycera, Meda, Merck & Co., Merck Research Laboratories, Novo Nordisk, PDL Biopharma, Pfizer Inc, Prometheus Laboratories, Protagonist, Receptos, Robarts Clinical Trials, Sandoz, Sanofi Genzyme, Satisfai Health, Shire Pharmaceuticals, Sigmoid Pharma, Specialty Rx, Sublimity, Takeda and TherAdvance. MTA has served as a trainer/lecturer for Cornerstones Health, Inc, Focus Medical Communications, Imedex, Janssen and Prime CME; and has served as a consultant or advisor to AbbVie, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Bristol‐Myers Squibb, Eli Lilly, Gilead Sciences, Prometheus Biosciences, Takeda and UCB Biopharma SRL. IL is an employee of IQVIA, which was a paid contractor to Pfizer in connection with the development of this manuscript and in providing statistical support. RM, NL, LS and JCW are all employees and stockholders of Pfizer Inc. BES has received consulting fees from 4D Pharma, AbbVie, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Boston Pharmaceuticals, Capella Biosciences, Celgene, Celltrion Healthcare, Eli Lilly, EnGene, Ferring Pharmaceuticals, Genentech, Gilead Sciences, Hoffmann‐La Roche, Immunic, Ironwood Pharmaceuticals, Janssen, Lyndra, MedImmune, Morphic Therapeutic, Oppilan Pharma, OSE Immunotherapeutics, Otsuka, Palatin Technologies, Pfizer Inc, Progenity, Prometheus Laboratories, Redhill Biopharma, Rheos Medicines, Seres Therapeutics, Shire Pharmaceuticals, Synergy Pharmaceuticals, Takeda, Target RWE, Theravance Biopharma R&D, TiGenix and Vivelix Pharmaceuticals; has received honoraria for speaking in CME programmes from Eli Lilly, Genetech, Gilead Sciences, Janssen, Pfizer Inc and Takeda; and has received research funding from Celgene, Janssen, Pfizer Inc, Takeda and Theravance Biopharma R&D. MC has served as a speaker, consultant and advisory member for, or received research funding from, AbbVie, Celltrion, Chiesi, Faes Farma, Falk Pharma, Ferring Pharmaceuticals, Gebro Pharma, Janssen, MSD, Otsuka Pharmaceuticals, Pfizer Inc, Roche, Shire Pharmaceuticals, Takeda and Tillotts Pharma.

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85125578187&partnerID=8YFLogxK

U2 - 10.1111/apt.16848

DO - 10.1111/apt.16848

M3 - Article

C2 - 35246988

AN - SCOPUS:85125578187

SN - 0269-2813

VL - 55

SP - 1534

EP - 1544

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 12

ER -